Open AccessImmune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression
Author(s) -
Minehiko Inomata,
Naoki Takata,
Isami Mizushima,
Kenji Azechi,
Kenya Hayashi,
Kotaro Tokui,
Chihiro Taka,
Seisuke Okazawa,
Kenta Kambara,
Shingo Imanishi,
Takeshi Miwa,
Ryuji Hayashi,
Shoko Matsui,
Kazuyuki Tobe
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10023
Subject(s) - medicine , lung cancer , oncology , proportional hazards model , cancer , pd l1 , immunotherapy , immune system , immune checkpoint , retrospective cohort study , tumor progression , metastasis , immunology
We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy.